Hugel introduces visiting doctors to Korean aesthetics
Predicted impact: Low
Hugel휴젤
145020 · KOSDAQ · ₩145020 · 휴젤
₩183,300▲ ₩1,800 (0.99%)End-of-day · Oct 29, 2026 · End-of-day prices.
Price · 1Y −30.04%
- Market cap
- ₩2.3T
- Enterprise value
- ₩1.7T
- P/E
- 14.5×
- P/B
- 2.2×
- Dividend yield
- 0.0%
- ROE
- 15.0%
- Net margin
- 32.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−40.6% from the high
₩163,700Today: ₩178,000 – ₩183,600₩308,500
Returns
- 1W+1.4%
- 1M0.0%
- 3M−18.4%
- 6M−27.4%
- YTD−20.5%
- 1Y−30.0%
- Volume today
- 42,903
- 0.8× the 20-day average
- Traded today
- ₩7.7B
- Listed shares
- 12,515,173
- EPS (12 months)
- ₩12,623
- Earnings yield 6.9%
AI research · InitiationHugel: Shares Down Sharply Over Past Year While Margins and Returns Stay HighThe filed numbers show steady revenue growth, high margins, strong cash generation and very low leverage, and the P/E of 14.4 is lower than the 20.6 at the end of 2025 and below the peers that report one.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 41 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Routine filings only, with no clear positive or negative news. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat-1.5% over the last month; the price is above its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
- StreetSteady2 brokers, average target 61% from the price; last 30 days: 0 raised, 0 cut.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 29: sell ₩667M at the close (7.1% of 20-day average trading value)
On its 12 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 27.3% of trading value and pointed the same way 7 of 12 times.
- 2× KODEX KOSDAQ150 Leverage −₩464M
- -1× KODEX KOSDAQ150 Futures Inverse −₩114M
- 2× TIGER KOSDAQ150 Leverage −₩57M
- 2× RISE KOSDAQ150 Futures Leverage −₩22M
- -1× TIGER KOSDAQ150 Futures Inverse −₩3.8M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1500.9%
- KODEX KOSDAQ150 Leverage2×0.9%
- TIGER KOSDAQ1500.9%
- RISE KOSDAQ1500.9%
- TIGER KOSDAQ150 Leverage2×0.9%
- ACE KOSDAQ 1500.9%
- KIWOOM KOSDAQ1500.9%
- SOL KOSDAQ1500.9%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 182,700
Basis −0.33% · implied rate −8.5%
Open interest 2,650 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Hugel stock overview
Hugel (휴젤, KRX: 145020) is listed on KOSDAQ, in the Biotech & Pharma sector. The company researches, develops and manufactures biopharmaceuticals based on A-type botulinum toxin, derived from the Clostridium botulinum microorganism. Its shares closed at ₩183,300 on Oct 29, 2026, up 0.99% on the day, giving it a market value of ₩2.3T.
Key facts
- Market cap
- ₩2.3T
- Sector
- Biotech & Pharma
- Latest price change
- +0.99%
- As of
- Oct 29, 2026
- Main business
- The company researches, develops and manufactures biopharmaceuticals based on A-type botulinum toxin, derived from the Clostridium botulinum microorganism.
Quick answers about Hugel
- What does Hugel do?
- The company researches, develops and manufactures biopharmaceuticals based on A-type botulinum toxin, derived from the Clostridium botulinum microorganism. Its main products include Botulax (botulinum toxin) and The Chaeum (HA filler), which it sells through its sales and marketing division, and its subsidiary Acros develops and manufactures HA dermal fillers. The products are used in aesthetic treatments such as wrinkle reduction and in medical treatments across fields including ophthalmology, dentistry, neurology and urology.
- What is the market cap of Hugel?
- The market capitalisation of Hugel was ₩2.3T at the close on Oct 29, 2026.
- What is the analyst target price for Hugel?
- The average target price of 2 brokers covering Hugel is ₩295,000 (range ₩280,000 to ₩310,000), 60.9% above versus the latest price, based on each broker's latest public report within six months.
- Who are the largest shareholders of Hugel?
- According to the latest official filings, the largest reported holders are Aphrodite Acquisition Holdings LLC (45.58%, as of Aug 4, 2026); MassachusettsFinancialServicesCompany (5.05%, as of May 13, 2026); MFS International New Discovery Fund (3.46%, as of Jun 30, 2026).
- When is the next earnings report from Hugel?
- Korean companies rarely announce results dates in advance. Based on when Hugel filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Hugel?
- Yes. The National Pension Service held 2.29% of Hugel shares as of Dec 31, 2025.
Company profile
The company researches, develops and manufactures biopharmaceuticals based on A-type botulinum toxin, derived from the Clostridium botulinum microorganism. Its main products include Botulax (botulinum toxin) and The Chaeum (HA filler), which it sells through its sales and marketing division, and its subsidiary Acros develops and manufactures HA dermal fillers. The products are used in aesthetic treatments such as wrinkle reduction and in medical treatments across fields including ophthalmology, dentistry, neurology and urology.
Written by AI from the company's latest annual report.
- Korean name
- 휴젤
- Sector
- Biotech & Pharma
- Business group
- GS
- CEO
- Doohyun Chang
- Founded
- Nov 2001
- Listed
- Dec 2015
- Listed shares
- 12,515,173
- Fiscal year ends
- Month 12
- Website
- www.hugel.co.kr
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent news
Recent filings
See all- Investor relations (IR) eventOct 28, 2026
- Advance Notice of Earnings Results DisclosureOct 28, 2026
- Investor relations (IR) eventSep 30, 2026
- Insider shareholding reportSep 30, 2026
- Investor relations (IR) eventSep 14, 2026
Titles in Korean until English translations are added.
Also known as: Hugel / 휴젤 / 145020 / KRX:145020
Source: KRX statistical information